Latest News and Press Releases
Want to stay updated on the latest news?
-
Treatment refractory, immunologically cold, hepatic tumor type37% reduction and 83% stabilization of treated disease (2D-EASL)Overall survival of 11 months for checkpoint inhibition-naïve patients;...
-
Treatment refractory, immunologically cold, hepatic tumor type50% reduction of treated disease; 83% stabilization of overall patient disease (RECIST)Median progression-free survival not reached (by CT...